Stock EPRSQ EPIRUS BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

EPIRUS Biopharmaceuticals, Inc. Stock

Equities

EPRSQ

US29428P1075

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for EPIRUS Biopharmaceuticals, Inc. -.--% -.--%
2018 Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
2018 Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q). CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials (USD)

Sales 2014 0 Sales 2015 0.7 Capitalization 75.33M
Net income 2014 -41M Net income 2015 -52M EV / Sales 2014 14,770,294,750 x
Net cash position 2014 14.18M Net cash position 2015 16.68M EV / Sales 2015 83,658,631 x
P/E ratio 2014
-0.83 x
P/E ratio 2015
-1.35 x
Employees -
Yield 2014 *
-
Yield 2015
-
Free-Float 100%
More Fundamentals * Assessed data

Chart EPIRUS Biopharmaceuticals, Inc.

Dynamic Chart

Latest news about EPIRUS Biopharmaceuticals, Inc.

Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q). CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million. CI
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc. CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index CI
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations CI
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination CI
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc.. CI
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million. CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes CI
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
More news

Highs and lows

3 years
0.00
Extreme 0.00000000
0.02
5 years
0.00
Extreme 0.00000000
0.24
10 years
0.00
Extreme 0.00000000
16.90
More quotes

Company Profile

EPIRUS Biopharmaceuticals, Inc. is in bankruptcy.
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EPIRUS BIOPHARMACEUTICALS, INC. Stock EPIRUS Biopharmaceuticals, Inc.
-.--% 26
MODERNA, INC. Stock Moderna, Inc.
+44.48% 54.04B
LONZA GROUP AG Stock Lonza Group AG
+43.57% 41.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.86% 41.92B
CELLTRION, INC. Stock Celltrion, Inc.
-7.59% 28.35B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.30% 26.35B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.83% 19B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.15% 13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.40% 12.28B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.15% 12.19B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EPRSQ Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW